GENEVA, Oct. 5 -- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. filed a patent application (CN2026/085481) for “USE OF ANTI-CD40 ANTIBODY IN TREATMENT OF TUMOR”. With publication no. WO/2026/200872, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 39/395
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....